Citations 1
INSPIRE: A randomized phase III trial of intravenous rigosertib in patients with higher-risk myelodysplastic syndromes (HR-MDS) after failure of hypomethylating agents (HMAs)—Study design informed by subgroup analyses of ONTIME.
Garcia‐Manero, Guillermo , Al‐Kali, Aref , Baer, Maria R. , Collins, Robert H. , Shammo, Jamile M. , Raza, Azra , Silverman, Lewis R. , Azarnia, N., Fruchtman, Steven, Snyder, Barbara R, Fenaux, Pierre , Roboz, Gail J. , Platzbecker, Uwe , Kambhampati, Suman , Godley, Lucy A. , Santini, Valeria
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: TPS7077-TPS7077
